InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Bolar provisions in India's patent law


In May 2003, when India's Patent Act was amended, a new Section 107A was introduced. This provided for a research exemption as an exception to the general rules of patent infringement. Commonly known as a Bolar provision, this research exemption enables a manufacturer of generic drugs to use a patented invention to obtain marketing approval without the patent owner's permission before the patent expires. The generic drug maker...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

RT @TomMitcheson: Manf. who knows (incl. constructive knowledge) or cd reasonably foresee drug will be used to infringe enough. Warner Lamb…

May 28 2015 10:52 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @TomMitcheson: 2nd medical use patent. Subjective intent not reqd. to infringe. +CA reinstates claim for contrib infringement. Warner La…

May 28 2015 10:52 ·  reply ·  retweet ·  favourite
ManagingIP profile

@filemot @WithersRogers We can all identify with that. Maybe time for a trip to Leamington Spa?

May 28 2015 09:50 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements